Evidence map›Paper›PMID 32201138›Full record

ArticleVaccine2020

Adverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad, Pakistan.

Farah Naz Qamar, Mohammad Tahir Yousafzai, Asif Khaliq, Sultan Karim, Hina Memon, Amber Junejo, Inayat Baig, Najeeb Rahman, Shafqat Bhurgry, Hina Afroz and 1 more

2 registry-linked trialsOpen access · hybridAbstract read
In one paragraph

Article in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05162482 phase2unknown statusnot on this mapstarted 2022, after this paper: background citation

Immunogenicity and Safety of Heterologous Combinations of COVID-19 Vaccines Available Under Emergency Use Authorization in Pakistan: A Randomized Phase II Trial

TypeinterventionalSponsorAga Khan University Hospital, PakistanRan2022 to 2024Enrolled1,680ConditionsCOVID 19 VaccineArmsBIBP (CNBG, Sinopharm) WIV, CanSinoBIO, AstraZeneca ChAdOx
NCT05475379 phase1 / phase2completednot on this mapstarted 2022, after this paper: background citation

A Randomized Control, Double Blinded, Non-inferiority Trial to Evaluate the Immunogenicity and Safety of Typhoid Vi Conjugate Vaccine 'Typhocon' in Bangladeshi Healthy Population

TypeinterventionalSponsorInternational Centre for Diarrhoeal Disease Research, BangladeshRan2022 to 2023Enrolled630ConditionsTyphoidArmsTyphoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT)
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Evaluation of Vaccine Safety After the First Public Sector Introduction of Typhoid Conjugate Vaccine-Navi Mumbai, India, 2018.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
  15. Article
  16. Article
  17. Enteric fever.BMJ (Clinical research ed.) · 2021
    Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Farah Naz QamarDept. of Pediatrics and Child Health, Aga Khan University Karachi, Pakistan.
Mohammad Tahir YousafzaiDept. of Pediatrics and Child Health, Aga Khan University Karachi, Pakistan; Kirby Institute, University of New South Wales, Sydney, Australia. Electronic address: m.tahir.yousafzai@gmail.com.
Asif KhaliqDept. of Pediatrics and Child Health, Aga Khan University Karachi, Pakistan.
Sultan KarimDept. of Pediatrics and Child Health, Aga Khan University Karachi, Pakistan.
Hina MemonDept. of Pediatrics and Child Health, Aga Khan University Karachi, Pakistan.
Amber JunejoDept. of Pediatrics and Child Health, Aga Khan University Karachi, Pakistan.
Inayat BaigDept. of Pediatrics and Child Health, Aga Khan University Karachi, Pakistan.
Najeeb RahmanDept. of Pediatrics and Child Health, Aga Khan University Karachi, Pakistan.
Shafqat BhurgryDept. of Pediatrics, Taluka Hospital Qasimabad, Pakistan.
Hina AfrozShah Bhitai Hospital, Latifabad, Pakistan.
Uzma SamiShah Bhitai Hospital, Latifabad, Pakistan.
Aga Khan University · PKMayo Hospital · PKUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pakistan is facing the world's largest outbreak of extensively drug-resistant (XDR) Typhoid. Vaccination campaign for children aged 6 months to 10 years old with Typhoid Conjugate Vaccine (Typbar-TCV®) was conducted in high-risk areas of Hyderabad during 2018. About 207,000 children were vaccinated. Here we report the adverse events following immunization (AEFI) during the campaign. The campaign was carried out using outreach and fixed centre strategy. Community mobilizers visited each household to perform line listing and mobilize parents with age-eligible children. Children were observed for 30 min post-vaccination. Two-pronged strategy was used for ascertainment of AEFI. A 24/7 hotline number was provided to all parents/caretakers (n = 199,861) to report AEFI during 14 days following immunization. An age-stratified (n = 7139 children) were actively followed at days 7 and 14 for the ascertainment of AEFI. All AEFI were examined by three trained medical officers. A structured questionnaire using Brighton collaboration criteria with level 3 diagnostic certainty was used for the recording of AEFI. Data were analysed using Microsoft Excel Office 365. Overall, 499 AEFI (433 in the subset actively followed and 66 self-reported through hotline) were observed. The rate of AEFI was significantly higher among very young children (age group 6 to 12 months) as compared to 2 to 3 years old children (0.54% vs. 0.33% respectively; p-value < 0.001). Fever was the most common AEFI self-reported through the hotline (38/199,861 = 0.02%) and among the subset followed actively for 14 days (206/7139 = 2.89%). Fever was followed by local reactogenicity 10/199,861(0.01%), and 134/7139 (1.88%) through self-reported hotline and active follow-up, respectively. No serious AEFI was observed. Administration of a single dose of Typbar-TCV among children aged 6 months to 10 years old during an outbreak setting of Hyderabad Pakistan was safe.

Indexed as

Typhoid FeverTyphoid-Paratyphoid VaccinesAdverse Drug Reaction Reporting SystemsChildChild, PreschoolDisease OutbreaksHumansImmunizationInfantPakistanVaccinationVaccines, ConjugateTyphoid-Paratyphoid VaccinesVaccines, ConjugateAdverse eventsAEFICampaignSalmonella TyphiTypbar-TCVVaccination

Identifiers

PMID32201138
PMCPMC7166079
OpenAlexW3012272949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.